The ROCK inhibitor eye drop accelerates corneal endothelium wound healing

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 4, 2013, Pages 2439-2502

  Okumura, Naoki ^a,b   Koizumi, Noriko ^b   Kay, EunDuck P ^b   Ueno, Morio ^a   Sakamoto, Yuji ^b   Nakamura, Shinichiro ^c   Hamuro, Junji ^a   Kinoshita, Shigeru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Corneal endothelial cells; Rho kinase; ROCK inhibitor; Wound healing

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMIDE; ENZYME INHIBITOR; EYE DROPS; PROTEIN ZO1; PYRIDINE DERIVATIVE; RHO KINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORNEA ENDOTHELIUM; ENDOTHELIAL DYSFUNCTION; FEMALE; HAPLORHINI; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SLIT LAMP; WOUND HEALING; ANIMAL; BLUNT TRAUMA; CELL COUNT; CORNEA EDEMA; CORNEAL ENDOTHELIAL CELL LOSS; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EYE INJURY; INJURY; MACACA FASCICULARIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TOPICAL DRUG ADMINISTRATION; ULTRASTRUCTURE;

ADMINISTRATION, TOPICAL; AGED; AMIDES; ANIMALS; CELL COUNT; CORNEAL EDEMA; CORNEAL ENDOTHELIAL CELL LOSS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, CORNEAL; ENZYME INHIBITORS; EYE INJURIES; FEMALE; HUMANS; MACACA FASCICULARIS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PYRIDINES; RHO-ASSOCIATED KINASES; SODIUM-POTASSIUM-EXCHANGING ATPASE; WOUND HEALING; WOUNDS, NONPENETRATING; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84875929599     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11320     Document Type: Article

References (33)

1. Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379:1749-1761.
2. Anshu A, Price MO, Tan DT, Price FW Jr. Endothelial keratoplasty: a revolution in evolution. Surv Ophthalmol. 2012;57:236-252.
3. Ishino Y, Sano Y, Nakamura T, et al. Amniotic membrane as a carrier for cultivated human corneal endothelial cell transplantation. Invest Ophthalmol Vis Sci. 2004;45:800-806.
4. Mimura T, Yamagami S, Yokoo S, et al. Cultured human corneal endothelial cell transplantation with a collagen sheet in a rabbit model. Invest Ophthalmol Vis Sci. 2004;45:2992-2997.
5. Mimura T, Yokoo S, Araie M, Amano S, Yamagami S. Treatment of rabbit bullous keratopathy with precursors derived from cultured human corneal endothelium. Invest Ophthalmol Vis Sci. 2005;46:3637-3644.
6. Sumide T, Nishida K, Yamato M, et al. Functional human corneal endothelial cell sheets harvested from temperatureresponsive culture surfaces. FASEB J. 2006;20:392-394.
7. Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophthalmol Vis Sci. 2007;48:4519-4526.
8. Koizumi N, Sakamoto Y, Okumura N, et al. Cultivated corneal endothelial transplantation in a primate: possible future clinical application in corneal endothelial regenerative medicine. Cornea. 2008;27(suppl 1):S48-S55.
9. Okumura N, Koizumi N, Ueno M, et al. ROCK inhibitor converts corneal endothelial cells into a phenotype capable of regenerating in vivo endothelial tissue. Am J Pathol. 2012;181: 268-277.
10. Lu J, Lu Z, Reinach P, et al. TGF-beta2 inhibits AKT activation and FGF-2-induced corneal endothelial cell proliferation. Exp Cell Res. 2006;312:3631-3640.
11. Nakano Y, Oyamada M, Dai P, Nakagami T, Kinoshita S, Takamatsu T. Connexin43 knockdown accelerates wound healing but inhibits mesenchymal transition after corneal endothelial injury in vivo. Invest Ophthalmol Vis Sci. 2008;49: 93-104.
12. Hoppenreijs VP, Pels E, Vrensen GF, Treffers WF. Corneal endothelium and growth factors. Surv Ophthalmol. 1996;41: 155-164.
13. Okumura N, Koizumi N, Ueno M, et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011;95:1006-1009.
14. Okumura N, Ueno M, Koizumi N, et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophthalmol Vis Sci. 2009;50:3680-3687.
15. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science. 1995;269:1270-1272.
16. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998; 279:509-514.
17. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456.
18. Watanabe K, Ueno M, Kamiya D, et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol. 2007;25:681-686.
19. Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol. 2004;5: 355-366.
20. Okumura N, Koizumi N, Ueno M, et al. The new therapeutic concept of using a rho kinase inhibitor for the treatment of corneal endothelial dysfunction. Cornea. 2011;30(suppl 1): S54-S59.
21. Koizumi N, Okumura N, Kinoshita S. Development of new therapeutic modalities for corneal endothelial disease focused on the proliferation of corneal endothelial cells using animal models. Exp Eye Res. 2012;95:60-67.
22. Koizumi N, Okumura N, Ueno M, Nakagawa H, Hamuro J, Kinoshita S. Rho-associated kinase (ROCK) inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. In press.
23. Van Horn DL, Hyndiuk RA. Endothelial wound repair in primate cornea. Exp Eye Res. 1975;21:113-124.
24. Matsubara M, Tanishima T. Wound-healing of the corneal endothelium in the monkey: a morphometric study. Jpn J Ophthalmol. 1982;26:264-273.
25. Matsubara M, Tanishima T. Wound-healing of corneal endothelium in monkey: an autoradiographic study. Jpn J Ophthalmol. 1983;27:444-450.
26. Treffers WF. Human corneal endothelial wound repair. In vitro and in vivo. Ophthalmology. 1982;89:605-613.
27. Joyce NC. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 2003;22:359-389.
28. Balachandran C, Ham L, Verschoor CA, Ong TS, van der Wees J, Melles GR. Spontaneous corneal clearance despite graft detachment in descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2009;148:227-234. e221.
29. Price FW Jr, Price MO. Spontaneous corneal clearance despite graft detachment after descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2010;149:173-174. author reply 174-175.
30. Yamamoto M, Marui N, Sakai T, et al. ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle. Oncogene. 1993;8:1449-1455.
31. Yoshizaki H, Ohba Y, Parrini MC, et al. Cell type-specific regulation of RhoA activity during cytokinesis. J Biol Chem. 2004;279:44756-44762.
32. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50:17-24.
33. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216-3222.